2021年9月12日简报:云南新增本土确诊病例7例、福建莆田市累计发现6例确诊;第二代新冠疫苗已完成II期临床试验;66岁女科学家因mRNA疫苗获大奖

2021-09-12 MedSci整理 MedSci整理

截至北京时间2021年9月12日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过22506万例,新增447,178例,达到225,065,14

截至北京时间2021年9月12日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎COVID-19)病例超过22506万例,新增447,178例,达到225,065,141例。累计死亡病例463.7万例,达到4,637,532例。新增死亡为7,603例。康复为201,600,998例,重症和危重症病人达到103,269例;全球新冠确诊病例超过100万例的国家达35个,106个国家病例超10万例。昨日报道:2021年9月11日简报:新冠肺炎重症和死亡可能与自身阻断Ⅰ型干扰素作用的抗体有关;地塞米松不适用于预防新冠肺炎

云南新增本土确诊病例7例、无症状感染者1例

据云南省卫健委通报,9月11日0时至24时,云南省新增境外输入新冠肺炎确诊病例11例、无症状感染者3例。确诊病例治愈出院8例,无症状感染者解除隔离医学观察2例。截至9月11日24时,云南省现有确诊病例240例(本土7例,境外输入233例)、无症状感染者45例(本土1例、境外输入44例),均在定点医疗机构隔离治疗或医学观察。

蒙古国首次报告动物感染新冠病例

蒙古国国家人畜共患病研究中心主任朝格巴达尔赫11日通报说,该国至少在7只河狸身上检测到变异新冠病毒德尔塔毒株。被感染的河狸出现咳嗽、流鼻涕等症状,目前这些河狸已全部康复。

福建莆田市累计发现6例确诊、18例无症状感染者,此次疫情初步判定为德尔塔毒株

今天(11日)下午,福建省莆田市人民政府新闻办公室召开新闻发布会,通报疫情防控最新情况。据莆田市疾控中心介绍,截至11日16时,此次疫情累计发现6例确诊、18例无症状感染者。

福建省莆田市人民政府新闻办公室召开新闻发布会,通报疫情防控最新情况。目前已把本次疫情19个相关病例的标本送省疾控中心进行基因测序,采取溶解曲线法进行快筛,结果初步判定为德尔塔毒株,基因测序预计2—3天内会出来。

根据流调结果,判定仙游县枫亭镇秀峰村、耕丰村、九社村、兰友社区、霞街社区为中风险地区,仙游县枫亭镇铺头社区、麟山村为高风险地区。

第二代新冠疫苗已完成II期临床试验

对于第二代新冠疫苗的研发,科研攻关组疫苗研发专班工作组组长、国家卫生健康委科技发展中心主任郑忠伟表示,一是我国的疫苗研发单位已经开展Gamma株和Delta株的灭活疫苗研究,二是开展针对不同变异株的广谱或多价重组蛋白疫苗的研究,三是开展针对Beta株、Delta株的腺病毒载体疫苗和核酸疫苗的研发工作。国药集团中国生物党委书记朱京津表示,目前针对德尔塔和贝塔等变异毒株的疫苗已经制备出来了。广谱重组蛋白二代疫苗也已经研发出来,已经完成I 、II期临床试验。

阿根廷一小学出现聚集感染事件 该国发现首例“缪”毒株感染者

当地时间9月10日,阿根廷首都布宜诺斯艾利斯市一小学发生聚集感染事件,截至目前导致至少43名小学生的核酸检测结果呈阳性。目前,相关人员已经被隔离,卫生部门正在对病毒的变种和传播途径进行调查。此外,阿根廷日前发现首例新冠病毒“缪”毒株感染者,该名患者为33岁女性,现有轻微症状。

匈牙利将在本土生产中国新冠疫苗

当地时间9月10日,匈牙利外交与对外经济部国务秘书门采尔·陶马什(Menczer Tamás)宣布,该部与国药集团中国生物技术股份有限公司在布达佩斯签署了在匈生产国药新冠疫苗的谅解备忘录,双方同意最晚不超过10个月在匈建立生产疫苗的设施。

门采尔强调,接种疫苗是抗击新冠疫情的武器,“能制造并大规模接种疫苗的国家将更加安全”。

德国新增新冠肺炎确诊病例11214例 累计确诊4070295例

根据德国联邦疾控机构罗伯特·科赫研究所发布的最新数据,截至当地时间9月11日零时,德国累计新冠肺炎确诊病例4070295例,较前一日新增11214例;累计死亡病例92598例,较前一日新增45例。德国全国每10万人的7天感染率为82.8。

丹麦移除所有防疫限制:新冠不再对社会构成严重威胁

丹麦12岁以上的人超过80%都已接种了两针疫苗。

在为抑制新冠疫情实施了长达548天的限制措施之后,北欧国家丹麦将成为欧盟内首个解除所有新冠相关限制措施的国家。而美国约翰斯·霍普金斯大学统计数据显示,截至9月5日的前一周内,丹麦新增确诊数达4926例。

从10日起,丹麦进入夜总会等场所时不再需要出示作为疫苗接种证明的数字通行证,而数字通行证是该国最后被免除的新冠防护措施。而且,同新冠肺炎确诊患者有过密切接触的儿童也不再被要求送回家,只有感染者才需要被隔离。人们可以像往常一样回到办公室,学校也照常上课。

坐40年“冷板凳”后,66岁女科学家因mRNA疫苗获大奖

有“科学界的奥斯卡”之称的科学突破奖近日揭晓,生命科学奖、物理学奖、数学奖分别授予5个项目共9位科学家,每个项目奖金金额为300万美元(约合1933万人民币),被认为是科学和数学领域最“阔绰”的奖项。

获奖者中,包括在mRNA技术上做出开拓性贡献的Katalin Karikó(卡塔琳·卡里科)与Drew Weissman(德鲁·韦斯曼)。

142549691029287936.png

 

图片来源:科学突破奖官方

尤其值得注意的是mRNA疫苗的奠基者、匈牙利生物化学家卡塔琳·卡里科。在过去的40年时间里,卡塔琳的人生简历里写满了失败,经历过无数次的拒绝,直到2020年新冠疫情爆发,她在BioNTech主导研发的mRNA疫苗进入人们的视野,这位科学家才最终迎来她人生的高光时刻。

2022年科学突破奖的“生命科学突破奖”颁发给了3个项目共6位科学家,包括在mRNA技术上做出开拓性贡献的Katalin Karikó与Drew Weissman,开发二代DNA测序技术的Shankar Balasubramanian、David Klenerman和Pascal Mayer,以及探索神经退行性疾病分子基础的Jeffery W. Kelly。

美国本轮疫情见顶,已开始下降

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (17)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2088868, encodeId=3a9e20888686c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 28 07:10:30 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931564, encodeId=6c97193156440, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Jun 23 04:10:30 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947421, encodeId=7694194e42134, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Mon Feb 07 11:10:30 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653205, encodeId=166a1653205ca, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jan 16 15:10:30 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524965, encodeId=633b152496510, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon Sep 13 23:10:30 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573876, encodeId=766e15e3876c6, content=<a href='/topic/show?id=af0a44e03a4' target=_blank style='color:#2F92EE;'>#女科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44703, encryptionId=af0a44e03a4, topicName=女科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38cb15960013, createdName=zhty5342, createdTime=Mon Sep 13 23:10:30 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017042, encodeId=620a101e042aa, content=美国本轮疫情见顶,已开始下降,估计世界会太平不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 15:00:09 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017039, encodeId=c2d6101e039d3, content=<a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>第二代, beContent=null, objectType=article, channel=null, level=null, likeNumber=361, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=58063, encryptionId=4dbd580630b, topicName=新冠疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 14:59:28 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016687, encodeId=8899101668eab, content=mRNA疫苗的奠基者、匈牙利生物化学家卡塔琳·卡里科。在过去的40年时间里,卡塔琳的人生简历里写满了失败,经历过无数次的拒绝,直到2020年新冠疫情爆发,她在BioNTech主导研发的mRNA疫苗进入人们的视野,这位科学家才最终迎来她人生的高光时刻。2022年科学突破奖的“生命科学突破奖”颁发给了3个项目共6位科学家,包括在mRNA技术上做出开拓性贡献的Katalin Karikó与Drew Weissman,开发二代DNA测序技术的Shankar Balasubramanian、David Klenerman和Pascal Mayer,以及探索神经退行性疾病分子基础的Jeffery W. Kelly。, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sun Sep 12 09:20:20 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017038, encodeId=9d08101e038e4, content=期待中国新的疫苗上线, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 14:59:19 CST 2021, time=2021-09-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2088868, encodeId=3a9e20888686c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 28 07:10:30 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931564, encodeId=6c97193156440, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Jun 23 04:10:30 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947421, encodeId=7694194e42134, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Mon Feb 07 11:10:30 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653205, encodeId=166a1653205ca, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jan 16 15:10:30 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524965, encodeId=633b152496510, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon Sep 13 23:10:30 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573876, encodeId=766e15e3876c6, content=<a href='/topic/show?id=af0a44e03a4' target=_blank style='color:#2F92EE;'>#女科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44703, encryptionId=af0a44e03a4, topicName=女科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38cb15960013, createdName=zhty5342, createdTime=Mon Sep 13 23:10:30 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017042, encodeId=620a101e042aa, content=美国本轮疫情见顶,已开始下降,估计世界会太平不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 15:00:09 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017039, encodeId=c2d6101e039d3, content=<a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>第二代, beContent=null, objectType=article, channel=null, level=null, likeNumber=361, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=58063, encryptionId=4dbd580630b, topicName=新冠疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 14:59:28 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016687, encodeId=8899101668eab, content=mRNA疫苗的奠基者、匈牙利生物化学家卡塔琳·卡里科。在过去的40年时间里,卡塔琳的人生简历里写满了失败,经历过无数次的拒绝,直到2020年新冠疫情爆发,她在BioNTech主导研发的mRNA疫苗进入人们的视野,这位科学家才最终迎来她人生的高光时刻。2022年科学突破奖的“生命科学突破奖”颁发给了3个项目共6位科学家,包括在mRNA技术上做出开拓性贡献的Katalin Karikó与Drew Weissman,开发二代DNA测序技术的Shankar Balasubramanian、David Klenerman和Pascal Mayer,以及探索神经退行性疾病分子基础的Jeffery W. Kelly。, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sun Sep 12 09:20:20 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017038, encodeId=9d08101e038e4, content=期待中国新的疫苗上线, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 14:59:19 CST 2021, time=2021-09-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2088868, encodeId=3a9e20888686c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 28 07:10:30 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931564, encodeId=6c97193156440, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Jun 23 04:10:30 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947421, encodeId=7694194e42134, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Mon Feb 07 11:10:30 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653205, encodeId=166a1653205ca, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jan 16 15:10:30 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524965, encodeId=633b152496510, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon Sep 13 23:10:30 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573876, encodeId=766e15e3876c6, content=<a href='/topic/show?id=af0a44e03a4' target=_blank style='color:#2F92EE;'>#女科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44703, encryptionId=af0a44e03a4, topicName=女科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38cb15960013, createdName=zhty5342, createdTime=Mon Sep 13 23:10:30 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017042, encodeId=620a101e042aa, content=美国本轮疫情见顶,已开始下降,估计世界会太平不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 15:00:09 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017039, encodeId=c2d6101e039d3, content=<a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>第二代, beContent=null, objectType=article, channel=null, level=null, likeNumber=361, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=58063, encryptionId=4dbd580630b, topicName=新冠疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 14:59:28 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016687, encodeId=8899101668eab, content=mRNA疫苗的奠基者、匈牙利生物化学家卡塔琳·卡里科。在过去的40年时间里,卡塔琳的人生简历里写满了失败,经历过无数次的拒绝,直到2020年新冠疫情爆发,她在BioNTech主导研发的mRNA疫苗进入人们的视野,这位科学家才最终迎来她人生的高光时刻。2022年科学突破奖的“生命科学突破奖”颁发给了3个项目共6位科学家,包括在mRNA技术上做出开拓性贡献的Katalin Karikó与Drew Weissman,开发二代DNA测序技术的Shankar Balasubramanian、David Klenerman和Pascal Mayer,以及探索神经退行性疾病分子基础的Jeffery W. Kelly。, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sun Sep 12 09:20:20 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017038, encodeId=9d08101e038e4, content=期待中国新的疫苗上线, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 14:59:19 CST 2021, time=2021-09-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2088868, encodeId=3a9e20888686c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 28 07:10:30 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931564, encodeId=6c97193156440, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Jun 23 04:10:30 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947421, encodeId=7694194e42134, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Mon Feb 07 11:10:30 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653205, encodeId=166a1653205ca, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jan 16 15:10:30 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524965, encodeId=633b152496510, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon Sep 13 23:10:30 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573876, encodeId=766e15e3876c6, content=<a href='/topic/show?id=af0a44e03a4' target=_blank style='color:#2F92EE;'>#女科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44703, encryptionId=af0a44e03a4, topicName=女科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38cb15960013, createdName=zhty5342, createdTime=Mon Sep 13 23:10:30 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017042, encodeId=620a101e042aa, content=美国本轮疫情见顶,已开始下降,估计世界会太平不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 15:00:09 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017039, encodeId=c2d6101e039d3, content=<a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>第二代, beContent=null, objectType=article, channel=null, level=null, likeNumber=361, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=58063, encryptionId=4dbd580630b, topicName=新冠疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 14:59:28 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016687, encodeId=8899101668eab, content=mRNA疫苗的奠基者、匈牙利生物化学家卡塔琳·卡里科。在过去的40年时间里,卡塔琳的人生简历里写满了失败,经历过无数次的拒绝,直到2020年新冠疫情爆发,她在BioNTech主导研发的mRNA疫苗进入人们的视野,这位科学家才最终迎来她人生的高光时刻。2022年科学突破奖的“生命科学突破奖”颁发给了3个项目共6位科学家,包括在mRNA技术上做出开拓性贡献的Katalin Karikó与Drew Weissman,开发二代DNA测序技术的Shankar Balasubramanian、David Klenerman和Pascal Mayer,以及探索神经退行性疾病分子基础的Jeffery W. Kelly。, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sun Sep 12 09:20:20 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017038, encodeId=9d08101e038e4, content=期待中国新的疫苗上线, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 14:59:19 CST 2021, time=2021-09-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2088868, encodeId=3a9e20888686c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 28 07:10:30 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931564, encodeId=6c97193156440, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Jun 23 04:10:30 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947421, encodeId=7694194e42134, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Mon Feb 07 11:10:30 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653205, encodeId=166a1653205ca, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jan 16 15:10:30 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524965, encodeId=633b152496510, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon Sep 13 23:10:30 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573876, encodeId=766e15e3876c6, content=<a href='/topic/show?id=af0a44e03a4' target=_blank style='color:#2F92EE;'>#女科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44703, encryptionId=af0a44e03a4, topicName=女科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38cb15960013, createdName=zhty5342, createdTime=Mon Sep 13 23:10:30 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017042, encodeId=620a101e042aa, content=美国本轮疫情见顶,已开始下降,估计世界会太平不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 15:00:09 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017039, encodeId=c2d6101e039d3, content=<a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>第二代, beContent=null, objectType=article, channel=null, level=null, likeNumber=361, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=58063, encryptionId=4dbd580630b, topicName=新冠疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 14:59:28 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016687, encodeId=8899101668eab, content=mRNA疫苗的奠基者、匈牙利生物化学家卡塔琳·卡里科。在过去的40年时间里,卡塔琳的人生简历里写满了失败,经历过无数次的拒绝,直到2020年新冠疫情爆发,她在BioNTech主导研发的mRNA疫苗进入人们的视野,这位科学家才最终迎来她人生的高光时刻。2022年科学突破奖的“生命科学突破奖”颁发给了3个项目共6位科学家,包括在mRNA技术上做出开拓性贡献的Katalin Karikó与Drew Weissman,开发二代DNA测序技术的Shankar Balasubramanian、David Klenerman和Pascal Mayer,以及探索神经退行性疾病分子基础的Jeffery W. Kelly。, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sun Sep 12 09:20:20 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017038, encodeId=9d08101e038e4, content=期待中国新的疫苗上线, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 14:59:19 CST 2021, time=2021-09-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2088868, encodeId=3a9e20888686c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 28 07:10:30 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931564, encodeId=6c97193156440, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Jun 23 04:10:30 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947421, encodeId=7694194e42134, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Mon Feb 07 11:10:30 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653205, encodeId=166a1653205ca, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jan 16 15:10:30 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524965, encodeId=633b152496510, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon Sep 13 23:10:30 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573876, encodeId=766e15e3876c6, content=<a href='/topic/show?id=af0a44e03a4' target=_blank style='color:#2F92EE;'>#女科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44703, encryptionId=af0a44e03a4, topicName=女科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38cb15960013, createdName=zhty5342, createdTime=Mon Sep 13 23:10:30 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017042, encodeId=620a101e042aa, content=美国本轮疫情见顶,已开始下降,估计世界会太平不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 15:00:09 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017039, encodeId=c2d6101e039d3, content=<a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>第二代, beContent=null, objectType=article, channel=null, level=null, likeNumber=361, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=58063, encryptionId=4dbd580630b, topicName=新冠疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 14:59:28 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016687, encodeId=8899101668eab, content=mRNA疫苗的奠基者、匈牙利生物化学家卡塔琳·卡里科。在过去的40年时间里,卡塔琳的人生简历里写满了失败,经历过无数次的拒绝,直到2020年新冠疫情爆发,她在BioNTech主导研发的mRNA疫苗进入人们的视野,这位科学家才最终迎来她人生的高光时刻。2022年科学突破奖的“生命科学突破奖”颁发给了3个项目共6位科学家,包括在mRNA技术上做出开拓性贡献的Katalin Karikó与Drew Weissman,开发二代DNA测序技术的Shankar Balasubramanian、David Klenerman和Pascal Mayer,以及探索神经退行性疾病分子基础的Jeffery W. Kelly。, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sun Sep 12 09:20:20 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017038, encodeId=9d08101e038e4, content=期待中国新的疫苗上线, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 14:59:19 CST 2021, time=2021-09-13, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2088868, encodeId=3a9e20888686c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 28 07:10:30 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931564, encodeId=6c97193156440, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Jun 23 04:10:30 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947421, encodeId=7694194e42134, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Mon Feb 07 11:10:30 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653205, encodeId=166a1653205ca, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jan 16 15:10:30 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524965, encodeId=633b152496510, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon Sep 13 23:10:30 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573876, encodeId=766e15e3876c6, content=<a href='/topic/show?id=af0a44e03a4' target=_blank style='color:#2F92EE;'>#女科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44703, encryptionId=af0a44e03a4, topicName=女科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38cb15960013, createdName=zhty5342, createdTime=Mon Sep 13 23:10:30 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017042, encodeId=620a101e042aa, content=美国本轮疫情见顶,已开始下降,估计世界会太平不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 15:00:09 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017039, encodeId=c2d6101e039d3, content=<a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>第二代, beContent=null, objectType=article, channel=null, level=null, likeNumber=361, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=58063, encryptionId=4dbd580630b, topicName=新冠疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 14:59:28 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016687, encodeId=8899101668eab, content=mRNA疫苗的奠基者、匈牙利生物化学家卡塔琳·卡里科。在过去的40年时间里,卡塔琳的人生简历里写满了失败,经历过无数次的拒绝,直到2020年新冠疫情爆发,她在BioNTech主导研发的mRNA疫苗进入人们的视野,这位科学家才最终迎来她人生的高光时刻。2022年科学突破奖的“生命科学突破奖”颁发给了3个项目共6位科学家,包括在mRNA技术上做出开拓性贡献的Katalin Karikó与Drew Weissman,开发二代DNA测序技术的Shankar Balasubramanian、David Klenerman和Pascal Mayer,以及探索神经退行性疾病分子基础的Jeffery W. Kelly。, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sun Sep 12 09:20:20 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017038, encodeId=9d08101e038e4, content=期待中国新的疫苗上线, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 14:59:19 CST 2021, time=2021-09-13, status=1, ipAttribution=)]
    2021-09-13 病毒猎手

    美国本轮疫情见顶,已开始下降,估计世界会太平不少

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2088868, encodeId=3a9e20888686c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 28 07:10:30 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931564, encodeId=6c97193156440, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Jun 23 04:10:30 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947421, encodeId=7694194e42134, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Mon Feb 07 11:10:30 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653205, encodeId=166a1653205ca, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jan 16 15:10:30 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524965, encodeId=633b152496510, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon Sep 13 23:10:30 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573876, encodeId=766e15e3876c6, content=<a href='/topic/show?id=af0a44e03a4' target=_blank style='color:#2F92EE;'>#女科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44703, encryptionId=af0a44e03a4, topicName=女科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38cb15960013, createdName=zhty5342, createdTime=Mon Sep 13 23:10:30 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017042, encodeId=620a101e042aa, content=美国本轮疫情见顶,已开始下降,估计世界会太平不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 15:00:09 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017039, encodeId=c2d6101e039d3, content=<a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>第二代, beContent=null, objectType=article, channel=null, level=null, likeNumber=361, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=58063, encryptionId=4dbd580630b, topicName=新冠疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 14:59:28 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016687, encodeId=8899101668eab, content=mRNA疫苗的奠基者、匈牙利生物化学家卡塔琳·卡里科。在过去的40年时间里,卡塔琳的人生简历里写满了失败,经历过无数次的拒绝,直到2020年新冠疫情爆发,她在BioNTech主导研发的mRNA疫苗进入人们的视野,这位科学家才最终迎来她人生的高光时刻。2022年科学突破奖的“生命科学突破奖”颁发给了3个项目共6位科学家,包括在mRNA技术上做出开拓性贡献的Katalin Karikó与Drew Weissman,开发二代DNA测序技术的Shankar Balasubramanian、David Klenerman和Pascal Mayer,以及探索神经退行性疾病分子基础的Jeffery W. Kelly。, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sun Sep 12 09:20:20 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017038, encodeId=9d08101e038e4, content=期待中国新的疫苗上线, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 14:59:19 CST 2021, time=2021-09-13, status=1, ipAttribution=)]
    2021-09-13 病毒猎手
    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2088868, encodeId=3a9e20888686c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 28 07:10:30 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931564, encodeId=6c97193156440, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Jun 23 04:10:30 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947421, encodeId=7694194e42134, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Mon Feb 07 11:10:30 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653205, encodeId=166a1653205ca, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jan 16 15:10:30 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524965, encodeId=633b152496510, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon Sep 13 23:10:30 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573876, encodeId=766e15e3876c6, content=<a href='/topic/show?id=af0a44e03a4' target=_blank style='color:#2F92EE;'>#女科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44703, encryptionId=af0a44e03a4, topicName=女科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38cb15960013, createdName=zhty5342, createdTime=Mon Sep 13 23:10:30 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017042, encodeId=620a101e042aa, content=美国本轮疫情见顶,已开始下降,估计世界会太平不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 15:00:09 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017039, encodeId=c2d6101e039d3, content=<a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>第二代, beContent=null, objectType=article, channel=null, level=null, likeNumber=361, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=58063, encryptionId=4dbd580630b, topicName=新冠疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 14:59:28 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016687, encodeId=8899101668eab, content=mRNA疫苗的奠基者、匈牙利生物化学家卡塔琳·卡里科。在过去的40年时间里,卡塔琳的人生简历里写满了失败,经历过无数次的拒绝,直到2020年新冠疫情爆发,她在BioNTech主导研发的mRNA疫苗进入人们的视野,这位科学家才最终迎来她人生的高光时刻。2022年科学突破奖的“生命科学突破奖”颁发给了3个项目共6位科学家,包括在mRNA技术上做出开拓性贡献的Katalin Karikó与Drew Weissman,开发二代DNA测序技术的Shankar Balasubramanian、David Klenerman和Pascal Mayer,以及探索神经退行性疾病分子基础的Jeffery W. Kelly。, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sun Sep 12 09:20:20 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017038, encodeId=9d08101e038e4, content=期待中国新的疫苗上线, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 14:59:19 CST 2021, time=2021-09-13, status=1, ipAttribution=)]
    2021-09-12 yangchou

    mRNA疫苗的奠基者、匈牙利生物化学家卡塔琳·卡里科。在过去的40年时间里,卡塔琳的人生简历里写满了失败,经历过无数次的拒绝,直到2020年新冠疫情爆发,她在BioNTech主导研发的mRNA疫苗进入人们的视野,这位科学家才最终迎来她人生的高光时刻。2022年科学突破奖的“生命科学突破奖”颁发给了3个项目共6位科学家,包括在mRNA技术上做出开拓性贡献的Katalin Karikó与Drew Weissman,开发二代DNA测序技术的Shankar Balasubramanian、David Klenerman和Pascal Mayer,以及探索神经退行性疾病分子基础的Jeffery W. Kelly。

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2088868, encodeId=3a9e20888686c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Apr 28 07:10:30 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931564, encodeId=6c97193156440, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Thu Jun 23 04:10:30 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947421, encodeId=7694194e42134, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Mon Feb 07 11:10:30 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653205, encodeId=166a1653205ca, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Jan 16 15:10:30 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524965, encodeId=633b152496510, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon Sep 13 23:10:30 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573876, encodeId=766e15e3876c6, content=<a href='/topic/show?id=af0a44e03a4' target=_blank style='color:#2F92EE;'>#女科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44703, encryptionId=af0a44e03a4, topicName=女科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38cb15960013, createdName=zhty5342, createdTime=Mon Sep 13 23:10:30 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017042, encodeId=620a101e042aa, content=美国本轮疫情见顶,已开始下降,估计世界会太平不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 15:00:09 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017039, encodeId=c2d6101e039d3, content=<a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>第二代, beContent=null, objectType=article, channel=null, level=null, likeNumber=361, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=58063, encryptionId=4dbd580630b, topicName=新冠疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 14:59:28 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016687, encodeId=8899101668eab, content=mRNA疫苗的奠基者、匈牙利生物化学家卡塔琳·卡里科。在过去的40年时间里,卡塔琳的人生简历里写满了失败,经历过无数次的拒绝,直到2020年新冠疫情爆发,她在BioNTech主导研发的mRNA疫苗进入人们的视野,这位科学家才最终迎来她人生的高光时刻。2022年科学突破奖的“生命科学突破奖”颁发给了3个项目共6位科学家,包括在mRNA技术上做出开拓性贡献的Katalin Karikó与Drew Weissman,开发二代DNA测序技术的Shankar Balasubramanian、David Klenerman和Pascal Mayer,以及探索神经退行性疾病分子基础的Jeffery W. Kelly。, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Sun Sep 12 09:20:20 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017038, encodeId=9d08101e038e4, content=期待中国新的疫苗上线, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Sep 13 14:59:19 CST 2021, time=2021-09-13, status=1, ipAttribution=)]
    2021-09-13 病毒猎手

    期待中国新的疫苗上线

    0

相关资讯

2021年9月10日简报:中国完成德尔塔灭活疫苗临床前研究;莫德纳宣布研发新冠、流感二合一疫苗;美国75%成年人已至少接种一剂新冠疫苗

截至北京时间2021年9月10日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过22398万例,新增586,901例,达到223,981,05

2021年9月8日简报:国内接种新冠疫苗人数达10.95亿人,超21亿剂次,全国高风险区清零;灭活疫苗接种后采用腺病毒载体疫苗加强,效果可能更好;新冠变异病毒mu毒株覆盖美国全境

截至北京时间2021年9月8日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过22258万例,新增471,510例,达到222,584,667

2021年9月6日简报:全国新冠疫苗接种剂次超21亿,新冠肺炎灭活疫苗第三针加强补种方案已提交审批,国产mRNA疫苗仍然在路上

截至北京时间2021年9月6日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过22150万例,新增415,884例,达到221,507,899

ESMO Open:接or不接?对于抗癌治疗患者,BNT162b2 COVID-19疫苗效果如何?

抗肿瘤治疗患者对BNT162b2新冠mRNA疫苗的体液免疫反应降低,尤其是接受化疗或利妥昔单抗的患者。

2021年9月9日简报:全国除云南外,已无中高风险地区;我国新冠mRNA疫苗厂房建成交付;美国超500万名儿童感染新冠病毒

截至北京时间2021年9月9日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过22331万例,新增557,938例,达到223,317,519

2021年9月7日简报:国内新冠疫苗完成检验和批签发30亿剂;以色列计划推出第四针新冠疫苗;越南称将与新冠谨慎共存

截至北京时间2021年9月7日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过22192万例,新增380,278例,达到221,929,941